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Abstract
Background: The non-thrombotic effects of thrombin in cardiovascular tissues, as mediated via
the protease activated receptors (PARs), and particularly PAR-1, have been the focus of much
recent research. The aims of this study were to evaluate the effects of thrombin, a specific PAR-1
activating peptide (PAR1-AP), and a PAR-1 antagonist on human umbilical artery tone in vitro.
Methods: Human umbilical artery samples were obtained from 17 women at term. Arterial rings
were suspended under physiologic conditions for isometric recording. The in vitro effects of
thrombin (0.5 units/mL to 3 units/mL), PAR1-AP TFLLR-NH2 [10(-9) to 10(-6) M], and PAR-1
antagonist (N-trans cinnamoyl- p-fluoroPhe-p-guanidinoPhe-Leu-Arg-Orn-NH2) [10(-9) M to 10(-
5) M] on umbilical artery tone were measured.
Results: Both thrombin and TFLLR-NH2 exerted a potent cumulative vasodilatory effect on
human umbilical artery resistance (P < 0.001). The mean net maximal inhibition (MMI) for thrombin
was 53.05% (n = 6; SEM = 1.43) at tissue bath concentration of 3 units/mL. The MMI with TFLLR-
NH2 was 61.50 % (n = 6; SEM = 1.43) at bath concentration of 10(-6) M. In comparison to vehicle
control, the PAR-1 antagonist did not show a significant relaxant or contractile effect (P > 0.05).
Conclusion: These findings highlight a potential role for thrombin and PAR-1 receptors in vascular
regulation of feto-placental blood flow in normal pregnancy, and in association with the vascular
lesions associated with IUGR and pre-eclampsia.
Background
In disorders resulting in poor fetal growth, and in pre-
eclampsia, thrombotic lesions are frequently observed in
the maternal and fetal vascular components of the pla-
centa, [1-3] and hence have been implicated in the patho-
physiology of these conditions. In addition, it has been
reported that in vivo generation of thrombin, in maternal
plasma, is higher in patients with small for gestation age
fetuses and with pre-eclampsia, than in normal pregnancy
[4]. It is well established, for many years, that thrombin
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other cell and tissue types (smooth muscle cells, endothe-
lial cells, lymphocytes) [5,6] have been the subject of
more recent attention. It is now apparent that thrombin
can regulate target cells by cleaving and activating a family
of G-protein-coupled protease-activated receptors
(PARs)[5-7]. This proteolytic cleavage of PARs is mediated
by a family of enzymes that require serine within the
active site i.e. serine proteases [5]. There are 4 major PAR
subtypes (PAR1-4) with diverse reported functions in var-
ious tissues [6]. PAR activation has been closely linked to
inflammation [6,8], contraction of vascular [5] and non-
vascular [9,10] smooth muscle, and platelet activation [6].
Although PAR-1, PAR-3 and PAR-4 [11] are all known to
be thrombin receptors, the mechanism of activation by
thrombin at these different PARs varies [12,13].
There is growing evidence, from vascular tissue studies in
several animal models, that non-thrombotic thrombin-
mediated signalling events are central to the response to
the disease process typical of vascular lesion formation in
atherosclerosis [14]. The direct effects of thrombin on vas-
cular cells, via the PAR receptors, and particularly PAR-1,
have been the main focus of investigation for this hypoth-
esis. PARs 1, 3 and 4 are activated by thrombin [11], but
PAR-1 is activated at low thrombin concentrations and
most of what is known about thrombin signalling down-
stream of the receptors, has been derived from studies of
PAR-1 [14]. While other PAR subtypes are present in
human arterial vessels, it appears that PAR-1 is primarily
involved in endothelium-dependent relaxation to
thrombin and trypsin [15]. To our knowledge, there are
no data outlining the potential effects of thrombin, or spe-
cific PAR-1 receptor modulation, on the feto-placental cir-
culation, despite the critical role of thrombin in disorders
of this vasculature. The aims of this study were to evaluate
the direct effects of thrombin, the specific PAR-1 activat-
ing peptide (PAR1-AP), TFLLR-NH2 (Thr-Phe-Leu-Leu-
Arg-NH2), and the PAR-1 specific antagonist (N-trans cin-
namoyl -p-fluoroPhe-p-quanidinoPhe-Leu-Arg-Orn-
NH2) on human umbilical artery tone in vitro.
Methods
The study was carried out in the Department of Obstetrics
and Gynaecology, University College Hospital Galway,
Ireland between May 2002 and April 2003. Sections of
human umbilical cord approximately 10 cm in length
were excised from the proximal segment of the cord (i.e.
closest to the placental attachment) immediately after
elective cesarean delivery. Samples were obtained from 17
women after elective cesarean section at term and from
one patient after normal vaginal delivery. All pregnancies
were uncomplicated and there was no evidence of hyper-
tensive disease or intrauterine fetal growth restriction. The
mean maternal age was 32.47 years (range 25–40 years).
The median period of gestation was 38 weeks (range 37–
42 weeks). The reasons for cesarean section included pre-
vious cesarean section (n = 9), breech presentation (n =
6), previous myomectomy (n = 1) and unstable fetal lie (n
= 1). At the time of recruitment 4 women were nullipa-
rous and 13 women were parous.
Samples were immediately placed in cold buffered Krebs
Henseleit physiological salt solution (pH 7.4) of the fol-
lowing composition: potassium chloride 4.7 mmol/L,
sodium chloride 118 mmol/L, magnesium sulphate 1.2
mmol/L, calcium chloride 1.2 mmol/L, potassium phos-
phate 1.2 mmol/L, sodium bicarbonate 25 mmol/L and
glucose 11 mmol/L. Maternal written informed consent
was obtained prior to tissue collection, and the tissue col-
lection procedure was approved by the Research Ethics
Committee at University College Hospital Galway.
Umbilical arteries were carefully dissected free of Whar-
ton's Jelly and cut in rings 4–5 mm in axial length. Rings
were suspended individually on stainless steel hooks
inserted into their lumens and mounted under 2 g (30
mN) of isometric tension, in glass-jacketed tissue baths, as
previously described [16,17]. Each bath-contained 10 mL
of oxygenated (95% O2 / 5% CO2) Krebs Henseleit physi-
ological salt solution (PSS) at 37°C and pH 7.4. Rings
were allowed to equilibrate for 90 minutes with regular
washouts of PSS. During this interval, spontaneous tone
developed. After the equilibration period, the vessel rings
were challenged with 60 mM potassium chloride (KCl).
Three washouts with PSS were carried out once the maxi-
mum response had reached a plateau, and a 20 minute
recovery period was allowed in order that baseline be
attained again. The KCl challenge was performed three
times. After the last KCl challenge, 40 minutes recovery
was allowed, and contraction was then stimulated by bath
exposure of the vessel rings to 5-hydroxytriptamine (5-
HT) (10-7 M). Once maximum contractile response to 5-
HT was attained, the rings were allowed to remain at pla-
teau for 20 minutes. Concentration- effect experiments
were performed by cumulative additions of thrombin, the
PAR1-AP, or the PAR-1 antagonist to the tissue bath.
Thrombin was added to the tissue bath at an initial con-
centration of 0.5 units/mL, and this was increased at 20-
minute intervals to 1 unit/mL, 2 units/mL and 3 units/mL
respectively. The bath concentrations ranges investigated
for PAR1-AP were 1 nanomol/L, 10 nanomol/L, 100
nanomol/L and 1 micromol/L (i.e. 10-9 - 10-6M), and for
PAR-1 antagonist were 1 nanomol/L, 10 nanomol/L, 100
nanomol/L, 1 micromol/L and 10 micromol/L (i.e. 10-9-
10-5M), all at 20-minute intervals.
The effects of thrombin, PAR1-AP and PAR-1 antagonist
were demonstrated by expressing the mean amplitude cal-
culated during the 20-minute period following additionPage 2 of 7
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amplitude obtained in the 20 minutes prior to any drug
addition. This measurement represents percentage con-
tractility or tone, and subtracted from 100%, provides the
percentage relaxation value for each bath concentration of
vehicle and study compounds. The net relaxant effect of
each compound was calculated by subtracting the per-
centage contractility value calculated for its respective
vehicle (for thrombin, PAR1-AP or PAR-1 antagonist),
control experiment, at each similar bath concentration.
All of the umbilical artery samples used for experimenta-
tion for each compound were obtained from different
women (i.e. n = 6 for PAR1-AP), for example, was
achieved by using umbilical artery samples from 6 differ-
ent women). The allocation of umbilical artery samples
for the different experiments was entirely random.
Fresh Krebs Henseleit physiological salt solution was
made and buffered daily. KCl solutions were prepared on
the day of experimentation. A stock solution of 5-HT
(Sigma-Aldrich, Dublin, Ireland) was made up in de-ion-
ised water and diluted with Krebs solution. Thrombin was
purchased from Sigma-Aldrich (Dublin, Ireland) and a
stock solution of 1100 U/ml prepared in de-ionised water
and stored at -20°C. PAR1-AP was purchased from Tocris
Cookson Ltd (Bristol, UK) and a stock solution of 1 milli-
mol/L was prepared using deionized water, with subse-
quent dilutions in PSS. The PAR-1 antagonist was
prepared and assayed by methods previously described
[18]. The IC50 value for antagonist inhibition of platelet
aggregation stimulated with 1 micromol/L SFLLRN ago-
nist was determined to be 0.1 micromol/L. It was pre-
pared as a 10 millimol/L stock solution in
dimethysulphoxide (DMSO) and stored in room temper-
ature protected from direct light. Final bath concentra-
tions of DMSO, at the highest concentration of PAR-1
antagonist, did not exceed 1%, for both study and vehicle
control strips. Serial dilutions of thrombin, PAR1-AP and
the PAR-1 antagonist were made using Krebs Henseleit
physiological salt solutions.
Comparisons of measurements of amplitude for each
bath concentration of thrombin, PAR1-AP and the PAR-1
antagonist, or respective control vehicle, were made using
a one-way ANOVA. Post-hoc comparisons were made
using the Tukey HSD test. A P value <0.05 was accepted as
statistically significant. The statistical package SPSS ver-
sion 10 was used for statistical calculations.
Results
A recording from control experiments (i.e. without addi-
tion of vehicle, thrombin, PAR1-AP or PAR-1 antagonist)
demonstrating umbilical artery tone due to bath exposure
of the ring to serotonin, for the entire duration of an
experiment, is shown in Figure 1A. The mean net sponta-
neous relaxation of tone observed was 14.39% (SEM =
2.76). Thrombin exerted a potent and cumulative
vasodilatory effect on umbilical artery tone in comparison
to simultaneous vehicle (PSS) only experiments. A repre-
sentative recording of the effects of thrombin is shown in
Figure 1B. At bath concentrations at or greater than 0.5
units/mL thrombin exerted a significant vasodilatory
effect. The net vasodilatory effects of thrombin are pro-
vided in Table 1. The mean net inhibition of tone
observed, at maximum thrombin concentration investi-
gated (i.e. 3 units/mL) was 53.5% (SEM = 4.62; n = 6; P <
0.001).
TFLLR-NH2, the PAR1-AP, similarly exerted a cumulative
vasodilatory effect on umbilical artery tone. A representa-
tive recording of the cumulative effects of PAR1-AP are
shown in Figure 1C, with the mean difference in ampli-
tude measurements (i.e. in comparison to simultaneous
control experiments) provided in Table 1. The mean net
inhibition of tone observed, at maximum PAR1-AP con-
centration investigated (i.e. 10-6M / 1 micromol/L) was
61.5% (SEM = 1.43; n= 6; P < 0.001).
For the PAR-1 antagonist, N-trans cinnamoyl-p-fluoro-
Phe-p-guanidinoPhe-Leu-Arg-Orn-NH2, no relaxation of
umbilical artery tone in vitro was observed, in compari-
son to vehicle only control experiments. Figure 2A dem-
onstrates a representative recording of umbilical artery
tone, after exposure to vehicle only (i.e. DMSO added
cumulatively). The mean net relaxation of tone observed
with vehicle was 70.28% (SEM = 2.98). In Figure 2B, a
representative recording of the effects of cumulatively
increasing bath exposure of arterial rings to the PAR-1
antagonist is shown. The mean net maximal inhibition
exerted was 6.87% (SEM = 1.57; n = 6; P = 0.280). Finally,
there was no observed difference in the vasodilatory
effects of thrombin, PAR1-AP or the PAR-1 antagonist in
relation to parity.
Discussion
This study demonstrates that thrombin exerts a potent
vasodilatory effect on human umbilical artery vasculature
in vitro. While it is known that thrombin has an inhibi-
tory effect on vessel tone in other animal and human vas-
cular tissue types [19-21] this is the first report, to our
knowledge, of the direct effects of thrombin on human
umbilical artery vasculature. Receptors for thrombin, the
PAR family of receptors, are present on vascular smooth
muscle cells, and on endothelial cells [14,22], with the
effects of thrombin mediated mainly via the PAR 1, 3 and
4 receptor subtypes [11]. The potential physiological func-
tion of thrombin in mediating vascular tone in the umbil-
ical circulation in normal pregnancy is unknown. Our
findings also raise questions in relation to the role of the
non-thrombotic effects of thrombin in the feto-placentalPage 3 of 7
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Representative recording of A) Serotonin induced contraction of umbilical artery, B) Serotonin induced contraction followed 
by cumulative additions of Thrombin and C) Serotonin induced contraction followed by cumulative additions of PAR1-AP.
Table 1: Net inhibitory effect of thrombin, PAR-1 and PAR1-AP on human umbilical artery tone.
Thrombin (n = 6) (% ± SEM) PAR1-AP (n = 6) (% ± SEM) PAR-1 Antagonist (n = 6) (% ± SEM) (P Value)
0.5 U/ml #28.90 ± 2.60 10-9M *23.91 ± 5.64 10-9M 2.83 ± 3.05 (NS) (0.630)
1 U/ml *35.39 ± 3.91 10-8M *37.32 ± 2.29 10-8M 3.80 ± 2.33 (NS) (0.471)
2 U/ml *44.72 ± 2.31 10-7M *52.39 ± 1.28 10-7M 5.60 ± 3.74 (NS) (0.228)
3 U/ml *53.51 ± 4.62 10-6M *61.50 ± 1.43 10-6M 7.03 ± 5.74 (NS) (0.148)
10-5M 6.87 ± 4.48 (NS) (0.815)
Values presented represent the mean inhibitory effects on umbilical artery tone i.e. after adjusting for control / vehicle experiments. The values 
provided represent % inhibition ± standard error of the mean (SEM). The PAR1-AP used was Threonine-Phenylalanine-Leucine-leucine-Arginine-
NH2. The PAR-1 antagonist used was Ser- pFPhe-pGPe-Leu-Arg-Orn-NH2. The values were compared with amplitude measurements observed 
prior to drug addition (NS not significant, # P < 0.01, * P < 0.001).Page 4 of 7
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sia and intrauterine growth restriction, which are classi-
cally associated with thrombotic lesions or a relative
excess of thrombin [1-3]. The possibility that the vasodila-
tory effect of thrombin may serve to counteract the dimin-
ished perfusion associated with the pathophysiology of
these conditions, at least in the early stages of disease, is
one hypothesis. A further theory is that the much
enhanced uterine contractility elicited by thrombin and
PAR1-AP [13] may be concomitantly associated with a
feto-placental vasodilatory effect to maintain good utero-
placental blood flow.
We have not elucidated the exact mechanism, or mecha-
nisms, of the thrombin mediated alteration in vascular
tone in human umbilical artery. We have however dem-
Representative recordings of A) umbilical artery tone after serotonin induced contraction with exposure to vehicle only (i.e. DMSO added cumulatively), and B) the effects of cumulatively increasi g bath exposure of ar erial rings to Ser- pFPhe-pGP -L u-Arg-Orn-NH2 after serotonin indu d contra tionFigure 2
Representative recordings of A) umbilical artery tone after serotonin induced contraction with exposure to vehicle only (i.e. 
DMSO added cumulatively), and B) the effects of cumulatively increasing bath exposure of arterial rings to Ser- pFPhe-pGPe-
Leu-Arg-Orn-NH2 after serotonin induced contraction.Page 5 of 7
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of the arterial rings to the specific PAR1-AP, TFLLR-NH2.
PAR1-APs are recently designed small synthetic peptide
ligands which mimic the effects of proteases by binding
directly to the activation site of the PAR-1 receptor,
bypassing the need for proteolytic cleavage of the recep-
tor. Soluble peptide ligands, as PAR-APs are, can vary
greatly in potency as agonists in comparison with pro-
teases [10]. TFLLR-NH2 is reportedly one of the more
selective PAR1-APs and is deemed most preferable for pur-
poses of studying the physiologic role of PAR-1 [10]. In
view of the fact that PAR-1 function is central to a
thrombin-mediated effect in other tissues [11,14,15] and
that a PAR-1 mediated effect in human umbilical artery
vasculature is similar to that elicited by thrombin, the
findings from this study are suggestive of a major role for
PAR-1 in mediating the vasodilatory effect of thrombin in
umbilical artery vasculature. Other possible mechanisms,
and the potential role of PARs 3 and 4, have not been eval-
uated in this study.
The PAR-1 antagonist, N-trans cinnamoyl-p-fluoroPhe-p-
guanidinoPhe-Leu-Arg-Orn-NH2, did not alter umbilical
artery tone. This peptide is a competitive antagonist i.e., it
competes for the agonist binding site and does not appear
to have any other activity [23]. The direct effects of PAR-
antagonism had not previously been evaluated on umbil-
ical artery preparations in vitro, and hence their inclusion
in this study. We have also previously demonstrated that
this specific PAR-1 antagonist exerted a relaxant effect on
human myometrium in vitro, the mechanism of which is
unknown [24]. The results observed here serve to confirm
that N-trans cinnamoyl-p-fluoroPhe-p-guanidinoPhe-
Leu-Arg-Orn-NH2 is inactive towards the PAR-1 receptor.
The true role of PAR antagonists, in such experiments, is
for the purpose of investigation of the potential effects of
an agonist at a PAR subtype. Pre-incubation of the arterial
rings with PAR-1 antagonist, for example, should alter the
response elicited by PAR1-AP. Such experiments, with
selective blockade of the PAR subtypes, in normal and dis-
eased pregnancies, are a subject of further studies.
There are some limitations to this study. All umbilical
cord artery samples were obtained at elective cesarean sec-
tion. This was included in the design of the study in order
to maintain uniformity in terms of mode of delivery, and,
to avoid using cord samples that may have undergone
excessive traction in the third stage of labor at vaginal
delivery. It is unknown whether this latter point is valid,
or not, in studies using in vitro umbilical preparations.
We are currently performing comparative studies from
samples obtained at vaginal delivery to further evaluate
this matter. Secondly, the effects of thrombin and PAR-1
modulation, on smaller vessels in the feto-placenta circu-
lation (i.e. placental arteries), and in association with dis-
orders of pregnancy, would compliment our knowledge
of the importance of this pathway. Finally, there are limi-
tations in extrapolating from in vitro experiments to the in
vivo situation, but the experiments conducted here repre-
sent a reliable and valid in vitro model for these vascular
preparations.
Conclusion
In conclusion, thrombin exerts a potent vasodilatory
effect on umbilical artery preparations in vitro. A similar
effect is also observed using a specific PAR1-AP. The
potential non-thrombotic role of thrombin, and PAR sub-
type modulation, in regulation of the feto-placental circu-
lation in normal pregnancy, and in pregnancies
complicated by hypertensive disease or intrauterine
growth restriction, is highlighted by these findings.
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